Why the study?
The cardiovascular benefits, risks, and potential influencing factors of menopause hormone therapy in postmenopausal women were not completely clear.
Does menopause hormone therapy reduce all-cause death and cardiovascular events in postmenopausal women?
Population
44,639 postmenopausal women across 33 RCTs
Comparison
Menopause hormone therapy vs placebo or no treatment
Design
Systematic review and random-effects meta-analysis of RCTs
Authors
Loading...
MHT should not be used for CV prevention in postmenopausal women; confirms neutral effects on death and events while highlighting stroke and VTE risks.
Does menopause hormone therapy reduce all-cause death and cardiovascular events in postmenopausal women?
Menopause hormone therapy does not reduce cardiovascular events or mortality in postmenopausal women overall, but increases the risk of stroke and venous thromboembolism, though initiation within 10 years of menopause may offer some cardiovascular benefits.
Gu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: